1602 pemphigus pts Rx w/ rituximab vs azathioprine or MMF. RTX pts had lower risk of MI (RR 0.45; P = .01), CVA (RR, 0.42; P < .001), PVD (0.47), HTN (0.48), hyperlipidemia (0.45), NIDDM (0.63), obesity (0.49). Mortality equal betw groups https://t.co/uvDDU5z8gp https://t.co/kJAg5xRKHz

Etoricoxib and Celecoxib may lower CVA risk. Taiwanese study of 10,857 newly Dx RA pts. Coxib use vs non-use compared re: future CVA. Celecoxib pts had reduced CVA (HR 0.67 @200/d; HR 0.22 if <3.5 yrs). Etoricoxib also (HR 0.35; 0.16–0.80) https://t.co/GQEp8N0uZb https://t.co/TxfyIemzBT

NRMP Results for rheumatology 2022 : - Adult Rheum: 97.8% of 272 fellow positions filled (41% US grads) (371 applied) - Pediatric Rheum: 69.2% of 39 positions filled (54% US grads) (29 applied) WE NEED MORE ADULT PROGRAMS AND MORE INTEREST IN PEDI RHEUM https://t.co/YpMhTPnDM4 https://t.co/Aa3EV57yij

AURORA1 RCT 📍Efficacy of voclosporin in LN III-V with UPC > 1.5g 💊VOC 23.7 mg BID vs. PCB 💊All got MMF 1g BID and GC 🥇#1 outcome: UPC < 0.5, stable 🫘 fx, ❌ GC > 10 mg -40% VOC v. 23% PCB (sig) -all measures favored VOC, but only sig. for UPC < 0.5

Topic Podcasts - JAK TYK2 https://t.co/DqfEj955aw https://t.co/HRj28berzF

A great read from Dr. Anthony Fauci as he steps down from leading the NIH NIAID research for nearly 40 years. He writes on pundits, need for specialty growth, evolution of vaccines and "it aint over till its over" is now "its never over" https://t.co/z0noGckIvx https://t.co/DJKG88V1mc

Estimated worldwide market for DMARDs in 2022 was $20.7 billion USD and is expected to rise at a 3.5% annual growth rate to $ 272 billion USD by 2030 https://t.co/futp7249rF https://t.co/QgxJR7TQNw

The Great Debate: To Treat or Not to Treat Pre RA Dr. Janet Pope ( @Janetbirdope) and Dr. Jonathan Kay ( @RheumKay) discuss the Great Debate, which Dr. Pope participated in, at #ACR22. https://t.co/PPXiX8MG6m https://t.co/Uy0kQd7XGz